<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624063</url>
  </required_header>
  <id_info>
    <org_study_id>TNT</org_study_id>
    <nct_id>NCT02624063</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)</brief_title>
  <official_title>Randomized Clinical Trial to Assess the Effectiveness of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 1 (TNT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of S達o Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of S達o Paulo</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to study the combination of Sofosbuvir in Combination With
      Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic
      Hepatitis C Virus (HCV) Genotype 1.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Non-cirrhotic Subjects With Sustained Virologic Response at Follow-up Week 12 (SVR12)</measure>
    <time_frame>At follow-up Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 was defined as hepatitis C virus RNA levels to be &lt; lower limit of quantitation ie, 12 IU/mL at follow-up Week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Rapid Virologic Response at Week 4 (RVR)</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>RVR was defined as hepatitis C virus RNA levels to be &lt; lower limit of quantitation ie, 12 IU/mL at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With End of Treatment Response (EOTR)</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>EOTR was defined as hepatitis C virus RNA levels to be &lt; lower limit of quantitation ie, 12 IU/mL at the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment safety measured by the number of incidence of serious adverse event (SAEs), discontinuations due to adverse event (AEs), Grade 3/4 AEs and Grade 3/4 clinical laboratory abnormalities through the end of treatment.</measure>
    <time_frame>From start of study treatment up to 7 days post last dose of study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Non-cirrhotic Subjects With Relapse at Follow-up Week 12 (SVR12)</measure>
    <time_frame>At follow-up Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Relapse was defined as hepatitis C virus RNA levels to be &gt; lower limit of quantitation ie, 12 IU/mL at follow-up Week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">394</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Daclatasvir + Sofosbuvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daclatasvir 60 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simeprevir + Sofosbuvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simeprevir 150 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir + Sofosbuvir</intervention_name>
    <description>Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks</description>
    <arm_group_label>Daclatasvir + Sofosbuvir</arm_group_label>
    <other_name>Solvaldi, Daklinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir + Sofosbuvir</intervention_name>
    <description>Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks</description>
    <arm_group_label>Simeprevir + Sofosbuvir</arm_group_label>
    <other_name>Sovaldi, Olysio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Genotype 1 HCV infection confirmed a positive test for anti-HCV antibody and detectable
        serum HCV RNA by PCR Never taken DAAs for HCV Patients must be able to understand and
        agree to/comply with the prescribed dosing regimens and procedures, report for regularly
        scheduled study visits, and reliably communicate with study personnel about adverse events
        and concomitant medications No Liver Cirrhosis Liver fibrosis Metavir F3 APRI &gt; 1,5 FIB4 &gt;
        3,25

        Exclusion Criteria:

        Infection with HCV other than GT-1 or subjects with mixed infections of any genotype Liver
        Cirrhosis Evidence of decompensated liver Subjects Infected with HIV-1 Hepatitis B virus
        (HBV) coinfection Liver or any other organ transplant (including hematopoietic stem cell
        transplants) other than cornea and hair Current or known history of cancer Documented or
        suspected hepatocellular carcinoma, as evidenced by previously obtained imaging studies or
        liver biopsy Pregnancy or impossibility to use birth control methods by the couple, or
        breastfeeding Regular use of: erythromycin, clarithromycin, rifampicin, rifabutin,
        telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole, voriconazole,
        dexamethasone, cisapride, rifapentine, carbamazepine, phenytoin, phenobarbital,
        oxcarbazepine, St. John's wort (Hypericum perforatum), silymarin (Silybum marianum) and
        some antiarrhythmic drugs such as amiodarone
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Outpatient Clinic of Viral Hepatitis (NUPAIG)</name>
      <address>
        <city>S達o Paulo</city>
        <zip>04025-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrique Pott-Junior, Dr</last_name>
      <phone>11-5571-5971</phone>
      <email>henriquepott@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Henrique Pott-Junior, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge F Senise, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adauto Castelo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 3, 2015</lastchanged_date>
  <firstreceived_date>December 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of S達o Paulo</investigator_affiliation>
    <investigator_full_name>Henrique Pott Junior</investigator_full_name>
    <investigator_title>Dr. Henrique Pott-Junior</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
